2017 Q4 Form 10-K Financial Statement
#000106282219000007 Filed on March 15, 2019
Income Statement
Concept | 2017 Q4 | 2017 Q3 | 2017 Q2 |
---|---|---|---|
Revenue | $33.97M | $27.67M | $12.09M |
YoY Change | 47.44% | -0.16% | -39.83% |
Cost Of Revenue | $500.0K | $599.0K | $537.0K |
YoY Change | |||
Gross Profit | $33.90M | $27.08M | $11.55M |
YoY Change | -2.32% | -42.51% | |
Gross Profit Margin | 99.81% | 97.84% | 95.56% |
Selling, General & Admin | $16.00M | $16.72M | $18.48M |
YoY Change | 13.48% | 36.38% | 119.52% |
% of Gross Profit | 47.2% | 61.77% | 159.96% |
Research & Development | $42.60M | $39.14M | $26.93M |
YoY Change | 62.6% | -25.5% | -44.14% |
% of Gross Profit | 125.66% | 144.55% | 233.19% |
Depreciation & Amortization | $900.0K | $900.0K | $1.000M |
YoY Change | 50.0% | 80.0% | 100.0% |
% of Gross Profit | 2.65% | 3.32% | 8.66% |
Operating Expenses | $58.60M | $56.46M | $45.95M |
YoY Change | 45.41% | -9.88% | -19.55% |
Operating Profit | -$29.02M | -$28.61M | -$33.49M |
YoY Change | -7.39% | -18.11% | -9.54% |
Interest Expense | -$2.200M | $1.619M | $1.614M |
YoY Change | 37.5% | -1.64% | -1.47% |
% of Operating Profit | |||
Other Income/Expense, Net | $600.0K | $415.0K | $448.0K |
YoY Change | 20.0% | -26.42% | -18.1% |
Pretax Income | -$26.30M | -$30.72M | -$35.06M |
YoY Change | 17.41% | -14.7% | -8.01% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$26.61M | -$29.81M | -$34.66M |
YoY Change | -17.92% | -17.23% | -9.07% |
Net Earnings / Revenue | -78.34% | -107.71% | -286.73% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$211.2K | -$290.7K | -$333.3K |
COMMON SHARES | |||
Basic Shares Outstanding | 105.6M shares | 105.6M shares | 105.2M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2017 Q4 | 2017 Q3 | 2017 Q2 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $310.8M | $196.8M | $231.2M |
YoY Change | -10.3% | -50.25% | -46.16% |
Cash & Equivalents | $61.66M | $83.29M | $30.71M |
Short-Term Investments | $249.1M | $113.5M | $200.5M |
Other Short-Term Assets | $4.434M | $4.458M | $10.17M |
YoY Change | 14.34% | 82.48% | 12.16% |
Inventory | $1.948M | $2.149M | $811.0K |
Prepaid Expenses | |||
Receivables | $4.825M | $10.60M | $5.014M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $322.0M | $214.0M | $247.2M |
YoY Change | -10.03% | -46.33% | -43.75% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $17.69M | $18.17M | $18.59M |
YoY Change | -8.78% | -8.5% | -8.66% |
Goodwill | $44.54M | $44.54M | $44.54M |
YoY Change | 0.0% | 0.0% | 0.0% |
Intangibles | $51.89M | $52.33M | $52.77M |
YoY Change | -2.76% | -1.93% | -1.1% |
Long-Term Investments | |||
YoY Change | |||
Other Assets | $429.0K | $429.0K | $428.0K |
YoY Change | -6.94% | -5.51% | -0.47% |
Total Long-Term Assets | $114.5M | $115.5M | $116.3M |
YoY Change | -2.72% | -2.32% | -1.98% |
TOTAL ASSETS | |||
Total Short-Term Assets | $322.0M | $214.0M | $247.2M |
Total Long-Term Assets | $114.5M | $115.5M | $116.3M |
Total Assets | $436.5M | $329.5M | $363.5M |
YoY Change | -8.22% | -36.26% | -34.87% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $38.76M | $52.63M | $43.86M |
YoY Change | -26.69% | 26.68% | 55.38% |
Accrued Expenses | $12.28M | $12.73M | $10.96M |
YoY Change | -61.75% | -61.32% | -54.24% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $14.09M | $14.63M | $15.16M |
YoY Change | -13.43% | -12.86% | -12.34% |
Total Short-Term Liabilities | $105.5M | $128.7M | $133.2M |
YoY Change | -35.93% | -24.33% | 1.66% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $231.6M | $85.51M | $85.38M |
YoY Change | 171.91% | 0.56% | 0.56% |
Other Long-Term Liabilities | $292.0K | $303.0K | $313.0K |
YoY Change | -63.73% | -87.88% | -97.77% |
Total Long-Term Liabilities | $231.9M | $85.82M | $85.70M |
YoY Change | 169.7% | -1.97% | -13.39% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $105.5M | $128.7M | $133.2M |
Total Long-Term Liabilities | $231.9M | $85.82M | $85.70M |
Total Liabilities | $368.3M | $251.1M | $257.2M |
YoY Change | 15.73% | -24.31% | -24.53% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$1.365B | -$1.353B | -$1.322B |
YoY Change | 9.19% | 11.09% | 11.88% |
Common Stock | $106.0K | $106.0K | $105.0K |
YoY Change | 0.95% | 1.92% | 0.96% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | $1.904M | $1.904M | $1.904M |
YoY Change | -43.47% | -43.47% | -43.47% |
Treasury Stock Shares | 122.0K shares | 122.0K shares | 122.0K shares |
Shareholders Equity | $68.27M | $78.38M | $106.3M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $436.5M | $329.5M | $363.5M |
YoY Change | -8.22% | -36.26% | -34.87% |
Cashflow Statement
Concept | 2017 Q4 | 2017 Q3 | 2017 Q2 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$26.61M | -$29.81M | -$34.66M |
YoY Change | -17.92% | -17.23% | -9.07% |
Depreciation, Depletion And Amortization | $900.0K | $900.0K | $1.000M |
YoY Change | 50.0% | 80.0% | 100.0% |
Cash From Operating Activities | -$33.70M | -$34.00M | -$32.20M |
YoY Change | -30.94% | -3.41% | -32.78% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | $0.00 | -$100.0K |
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$135.7M | $87.10M | $56.90M |
YoY Change | -339.75% | 156.93% | -7.63% |
Cash From Investing Activities | -$135.8M | $87.10M | $56.70M |
YoY Change | -340.35% | 156.93% | -7.8% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 147.8M | -500.0K | 3.700M |
YoY Change | 73800.0% | -129.41% | |
NET CHANGE | |||
Cash From Operating Activities | -33.70M | -34.00M | -32.20M |
Cash From Investing Activities | -135.8M | 87.10M | 56.70M |
Cash From Financing Activities | 147.8M | -500.0K | 3.700M |
Net Change In Cash | -21.70M | 52.60M | 28.20M |
YoY Change | -374.68% | 13050.0% | 107.35% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$33.70M | -$34.00M | -$32.20M |
Capital Expenditures | $0.00 | $0.00 | -$100.0K |
Free Cash Flow | -$33.70M | -$34.00M | -$32.10M |
YoY Change | -30.8% | -3.41% | -32.99% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2018 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2018 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2018 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2018 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | |
CY2018 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-12-31 | |
CY2018 | dei |
Document Type
DocumentType
|
10-K | |
CY2018 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001062822 | |
CY2019Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
106271927 | shares |
CY2018 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2018 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2018 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2018 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
CY2018Q2 | dei |
Entity Public Float
EntityPublicFloat
|
491500000 | USD |
CY2018 | dei |
Entity Registrant Name
EntityRegistrantName
|
LEXICON PHARMACEUTICALS, INC./DE | |
CY2018 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2018 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2018 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2018 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2017Q1 | lxrx |
Accumulated Excess Tax Benefits Recognizedas Deferred Tax Assets
AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets
|
6100000 | USD |
CY2017Q1 | lxrx |
Adjustmentto Accumulated Deficit
AdjustmenttoAccumulatedDeficit
|
2000000 | USD |
CY2001Q3 | lxrx |
Coelacanth Purchase Price
CoelacanthPurchasePrice
|
36000000 | USD |
CY2018Q4 | lxrx |
Convertible Debt Instrument Interest Rate Stated Percentage
ConvertibleDebtInstrumentInterestRateStatedPercentage
|
0.0525 | |
CY2018Q4 | lxrx |
Deferred Tax Assetremeasured
DeferredTaxAssetremeasured
|
165300000 | USD |
CY2018 | lxrx |
Cost Of Goods And Services Sold Period Reflecting Lower Average Per Unit Cost Of Materials
CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials
|
P18M | |
CY2018 | lxrx |
Debt Instrument Repurchase Percentage
DebtInstrumentRepurchasePercentage
|
1 | |
CY2018Q4 | lxrx |
Buildings Collateral
BuildingsCollateral
|
59200000 | USD |
CY2016 | lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
-703000 | USD |
CY2017 | lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
2101000 | USD |
CY2018 | lxrx |
Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
|
0 | USD |
CY2001Q3 | lxrx |
Coelacanth Goodwill
CoelacanthGoodwill
|
25800000 | USD |
CY2017Q4 | lxrx |
Deferred Tax Assets Section163j Lxrx
DeferredTaxAssetsSection163j_LXRX
|
0 | USD |
CY2017Q4 | lxrx |
Deferred Tax Assets Tax Credit Carryforwards Orphan Drug
DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
|
24524000 | USD |
CY2018Q4 | lxrx |
Deferred Tax Assets Tax Credit Carryforwards Orphan Drug
DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
|
24524000 | USD |
CY2017Q4 | lxrx |
Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
|
10896000 | USD |
CY2018Q4 | lxrx |
Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
|
10525000 | USD |
CY2018Q4 | lxrx |
Deferred Tax Liabilityfrom Reclassified Indefinitelived Intangible
DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible
|
4000000 | USD |
CY2017Q1 | lxrx |
Deferred Tax Liabilityfrom Reclassified Intangible Asset
DeferredTaxLiabilityfromReclassifiedIntangibleAsset
|
8700000 | USD |
CY2018 | lxrx |
Defined Contribution Plan Requisite Service Period
DefinedContributionPlanRequisiteServicePeriod
|
P4Y | |
CY2016 | lxrx |
Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
|
0.01 | |
CY2017 | lxrx |
Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
|
0.17 | |
CY2018 | lxrx |
Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
|
0.40 | |
CY2016 | lxrx |
Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
|
0.99 | |
CY2017 | lxrx |
Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
|
0.83 | |
CY2018 | lxrx |
Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
|
0.60 | |
CY2017 | lxrx |
Entity Wide Revenue Ipsen Percentage
EntityWideRevenueIpsenPercentage
|
0.18 | |
CY2016 | lxrx |
Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
|
0.90 | |
CY2017 | lxrx |
Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
|
0.66 | |
CY2018 | lxrx |
Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
|
0.53 | |
CY2007Q2 | lxrx |
Holdings Contribution To Icon
HoldingsContributionToIcon
|
45000000 | USD |
CY2014Q4 | lxrx |
Ipsen Maximum Regulatory And Commercial Milestones
IpsenMaximumRegulatoryAndCommercialMilestones
|
11800000 | USD |
CY2014Q4 | lxrx |
Ipsen Maximum Sales Milestones
IpsenMaximumSalesMilestones
|
72000000 | EUR |
CY2016Q3 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
6400000 | USD |
CY2017Q4 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
3800000 | USD |
CY2017Q4 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
3800000 | USD |
CY2018Q4 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
1300000 | USD |
CY2018Q3 | lxrx |
Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
|
5100000 | USD |
CY2014Q4 | lxrx |
Ipsen Revenue Allocatedto Committee Deliverable
IpsenRevenueAllocatedtoCommitteeDeliverable
|
100000 | USD |
CY2014Q4 | lxrx |
Ipsen Revenue Allocatedto Development Deliverable
IpsenRevenueAllocatedtoDevelopmentDeliverable
|
1700000 | USD |
CY2014Q4 | lxrx |
Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
|
21200000 | USD |
CY2017 | lxrx |
Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
|
1400000 | USD |
CY2016 | lxrx |
Ipsen Revenue Recognized
IpsenRevenueRecognized
|
7200000 | USD |
CY2017 | lxrx |
Ipsen Revenue Recognized
IpsenRevenueRecognized
|
16200000 | USD |
CY2018 | lxrx |
Ipsen Revenue Recognized
IpsenRevenueRecognized
|
4600000 | USD |
CY2017 | lxrx |
Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
|
100000 | USD |
CY2018 | lxrx |
Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
|
300000 | USD |
CY2018Q4 | lxrx |
Ipsen Total Payments To Date
IpsenTotalPaymentsToDate
|
45000000 | USD |
CY2014Q4 | lxrx |
Ipsen Total Upfront Payments
IpsenTotalUpfrontPayments
|
24500000 | USD |
CY2017 | lxrx |
Ipsenproductsales
Ipsenproductsales
|
800000 | USD |
CY2018 | lxrx |
Ipsenproductsales
Ipsenproductsales
|
1600000 | USD |
CY2018 | lxrx |
Lxrx Biologicscustomerconcentration
LXRXBiologicscustomerconcentration
|
0.25 | |
CY2018 | lxrx |
Lxrx Diplomatcustomerconcentration
LXRXDiplomatcustomerconcentration
|
0.14 | |
CY2018Q4 | lxrx |
Land Collateral
LandCollateral
|
2700000 | USD |
CY2010Q3 | lxrx |
Lexicon Paid Holdings Cash
LexiconPaidHoldingsCash
|
10000000 | USD |
CY2007Q2 | lxrx |
Lexicon Received Cash From Holdings
LexiconReceivedCashFromHoldings
|
15000000 | USD |
CY2007Q2 | lxrx |
Lexicon Sold Shares To Holdings
LexiconSoldSharesToHoldings
|
1092946 | shares |
CY2018Q3 | lxrx |
Mortgage Debt Balloon Payment Lxrx
MortgageDebtBalloonPayment_LXRX
|
10300000 | USD |
CY2018Q3 | lxrx |
Mortgage Debt Instrument Revere Lxrx
MortgageDebtInstrument_Revere_LXRX
|
12900000 | USD |
CY2018Q3 | lxrx |
Mortgage Debt Interest Rate Ceiling Revere Lxrx
MortgageDebtInterestRateCeiling_Revere_LXRX
|
0.075 | |
CY2018Q3 | lxrx |
Mortgage Debt Interest Rate Base Revere Lxrx
MortgageDebtInterestRate_Base_Revere_LXRX
|
0.055 | |
CY2018Q4 | lxrx |
Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
|
300000 | USD |
CY2018Q3 | lxrx |
Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
|
400000 | USD |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Number Of Development Milestones
ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones
|
4 | milestone |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Number Of Regulatory Milestones
ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones
|
4 | milestone |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Royalties Percentage
ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage
|
0.40 | |
CY2016Q4 | lxrx |
Number Of Positions Created Inception To Date
NumberOfPositionsCreatedInceptionToDate
|
1616 | job |
CY2018Q4 | lxrx |
Options Outstanding Equity Incentive Plan
OptionsOutstandingEquityIncentivePlan
|
5953831 | shares |
CY2018Q4 | lxrx |
Options Outstanding Non Employee Directors Equity Incentive Plan
OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
|
198551 | shares |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Commercial Costs Funded Percentage
ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage
|
0.40 | |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Development Costs Period
ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod
|
P3Y | |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Expiration Period
ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod
|
P10Y | |
CY2015Q4 | lxrx |
Research And Development Arrangement Contract To Perform For Others Number Of Commercial Milestones
ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones
|
6 | milestone |
CY2018Q4 | lxrx |
Restricted Stock Units Outstanding Equity Incentive Plan
RestrictedStockUnitsOutstandingEquityIncentivePlan
|
1285752 | shares |
CY2015Q4 | lxrx |
Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount
SanofiCommercializationCostsFundedbyLexiconMaximumAmount
|
100000000 | USD |
CY2015Q4 | lxrx |
Sanofi Development Milestones
SanofiDevelopmentMilestones
|
110000000 | USD |
CY2015Q4 | lxrx |
Sanofi Outcomes Study Milestone
SanofiOutcomesStudyMilestone
|
100000000 | USD |
CY2015Q4 | lxrx |
Sanofi Regulatory Milestones
SanofiRegulatoryMilestones
|
220000000 | USD |
CY2015Q4 | lxrx |
Sanofi Revenue Allocatedto Development Deliverable
SanofiRevenueAllocatedtoDevelopmentDeliverable
|
113800000 | USD |
CY2015Q4 | lxrx |
Sanofi Revenue Allocatedto Funding Deliverable
SanofiRevenueAllocatedtoFundingDeliverable
|
59400000 | USD |
CY2015Q4 | lxrx |
Sanofi Revenue Allocatedto License Deliverable
SanofiRevenueAllocatedtoLicenseDeliverable
|
126800000 | USD |
CY2016 | lxrx |
Sanofi Revenue Recognized
SanofiRevenueRecognized
|
71300000 | USD |
CY2017 | lxrx |
Sanofi Revenue Recognized
SanofiRevenueRecognized
|
60100000 | USD |
CY2018 | lxrx |
Sanofi Revenue Recognized
SanofiRevenueRecognized
|
33200000 | USD |
CY2015Q4 | lxrx |
Sanofi Sales Milestone Payments
SanofiSalesMilestonePayments
|
990000000 | USD |
CY2016 | lxrx |
Sanofi Salesof Clinical Trial Materials
SanofiSalesofClinicalTrialMaterials
|
6300000 | USD |
CY2017 | lxrx |
Sanofi Salesof Clinical Trial Materials
SanofiSalesofClinicalTrialMaterials
|
1900000 | USD |
CY2015Q4 | lxrx |
Sanofi Upfront Payment
SanofiUpfrontPayment
|
300000000 | USD |
CY2018 | lxrx |
Sanofirevenuefromfilingperformance Lxrx
Sanofirevenuefromfilingperformance_LXRX
|
8600000 | USD |
CY2016 | lxrx |
Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
|
11456 | shares |
CY2017 | lxrx |
Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
|
10248 | shares |
CY2018 | lxrx |
Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
|
20512 | shares |
CY2016 | lxrx |
Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
|
13.96 | |
CY2017 | lxrx |
Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
|
15.61 | |
CY2018 | lxrx |
Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
|
7.80 | |
CY2018Q4 | lxrx |
Shares Issued Pursuant To Restricted Stock Awards Non Employee Directors Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
|
103208 | shares |
CY2018Q4 | lxrx |
Shares Issued Pursuant To Restricted Stock Units Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
|
1451648 | shares |
CY2018Q4 | lxrx |
Shares Issued Pursuant To Stock Bonus Awards Equity Incentive Plan
SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
|
113940 | shares |
CY2016 | lxrx |
Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
|
0 | USD |
CY2018 | lxrx |
Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
|
0 | USD |
CY2016 | lxrx |
Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
|
3514000 | USD |
CY2017 | lxrx |
Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
|
4567000 | USD |
CY2018 | lxrx |
Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
|
5686000 | USD |
CY2016 | lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
3938000 | USD |
CY2017 | lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
4905000 | USD |
CY2018 | lxrx |
Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
|
6010000 | USD |
CY2018 | lxrx |
Stock Option Exercise Price As Percent Of Value Of Common Stock
StockOptionExercisePriceAsPercentOfValueOfCommonStock
|
1.00 | |
CY2018Q4 | lxrx |
Stock Options Exercised Equity Incentive Plan
StockOptionsExercisedEquityIncentivePlan
|
1909515 | shares |
CY2018Q4 | lxrx |
Stock Options Exercised Non Employee Directors Equity Incentive Plan
StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
|
0 | shares |
CY2010Q3 | lxrx |
Symphon Fair Value Of Base And Contingent Payments
SymphonFairValueOfBaseAndContingentPayments
|
45600000 | USD |
CY2016Q3 | lxrx |
Symphony Amendment Buyout
SymphonyAmendmentBuyout
|
21000000 | USD |
CY2010Q3 | lxrx |
Symphony Base Payment Discount Rate
SymphonyBasePaymentDiscountRate
|
0.14 | |
CY2012Q3 | lxrx |
Symphony Base Payment In Shares
SymphonyBasePaymentInShares
|
1891074 | shares |
CY2012Q3 | lxrx |
Symphony Base Payment Obligation
SymphonyBasePaymentObligation
|
35000000 | USD |
CY2010Q3 | lxrx |
Symphony Contingent Payment Discount Rate
SymphonyContingentPaymentDiscountRate
|
0.18 | |
CY2014Q4 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
5800000 | USD |
CY2015Q2 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
750000 | USD |
CY2016Q3 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
3200000 | USD |
CY2017Q1 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
10500000 | USD |
CY2017 | lxrx |
Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
|
10499000 | USD |
CY2010Q3 | lxrx |
Symphony Contingent Payment Maximum
SymphonyContingentPaymentMaximum
|
45000000 | USD |
CY2010Q3 | lxrx |
Symphony Contingent Payment Percentage
SymphonyContingentPaymentPercentage
|
0.50 | |
CY2014Q4 | lxrx |
Symphony Contingent Payment Total
SymphonyContingentPaymentTotal
|
11500000 | USD |
CY2014Q4 | lxrx |
Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
|
666111 | shares |
CY2017Q1 | lxrx |
Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
|
659905 | shares |
CY2010Q3 | lxrx |
Symphony Icon Goodwill
SymphonyIconGoodwill
|
18700000 | USD |
CY2010Q3 | lxrx |
Symphony Payment In Stock Limitation
SymphonyPaymentInStockLimitation
|
0.50 | |
CY2010Q3 | lxrx |
Symphony Regulatory Approval Payment
SymphonyRegulatoryApprovalPayment
|
15000000 | USD |
CY2010Q3 | lxrx |
Symphony Regulatory Approval Percentage Limit
SymphonyRegulatoryApprovalPercentageLimit
|
0.50 | |
CY2010Q3 | lxrx |
Symphony Regulatory Approval Reduction Percentage
SymphonyRegulatoryApprovalReductionPercentage
|
0.50 | |
CY2018Q4 | lxrx |
Tigm Maximum Exposure
TigmMaximumExposure
|
14200000 | USD |
CY2018Q4 | lxrx |
Tigm Per Job Payment Amount
TigmPerJobPaymentAmount
|
2415 | USD |
CY2018Q4 | lxrx |
Total Shares That May Be Issued Equity Incentive Plan
TotalSharesThatMayBeIssuedEquityIncentivePlan
|
15000000 | shares |
CY2018Q4 | lxrx |
Total Shares That May Be Issued Non Employee Directors Equity Incentive Plan
TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
|
600000 | shares |
CY2018Q4 | lxrx |
Totalvalueofsharesbynonemployeeinayear
Totalvalueofsharesbynonemployeeinayear
|
500000 | USD |
CY2005Q3 | lxrx |
Tx Enterprise Fund Award
TxEnterpriseFundAward
|
35000000 | USD |
CY2005Q3 | lxrx |
Tx Enterprise Fund Award To Texas Am University System
TxEnterpriseFundAwardToTexasAmUniversitySystem
|
15000000 | USD |
lxrx |
Xermelo Intangible Assets Finite Lived
XERMELOIntangibleAssetsFiniteLived
|
24700000 | USD | |
CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
38762000 | USD |
CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
17759000 | USD |
CY2017Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4825000 | USD |
CY2018Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5924000 | USD |
CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
12282000 | USD |
CY2018Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
14482000 | USD |
CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
58623000 | USD |
CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
60006000 | USD |
CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-222000 | USD |
CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-12000 | USD |
CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1435526000 | USD |
CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1447954000 | USD |
CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7452000 | USD |
CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
9472000 | USD |
CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
11696000 | USD |
CY2017Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4000 | USD |
CY2018Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4000 | USD |
CY2016 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
527000 | USD |
CY2017 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
599000 | USD |
CY2018 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
1336000 | USD |
CY2017 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1500000 | USD |
CY2018 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1800000 | USD |
CY2016 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
CY2017 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
CY2018 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
CY2017Q4 | us-gaap |
Assets
Assets
|
436539000 | USD |
CY2018Q4 | us-gaap |
Assets
Assets
|
284136000 | USD |
CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
321995000 | USD |
CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
173324000 | USD |
CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
249127000 | USD |
CY2018Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
79666000 | USD |
CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
202989000 | USD |
CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
46600000 | USD |
CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
61661000 | USD |
CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
80386000 | USD |
CY2017Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
61661000 | USD |
CY2018Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
80386000 | USD |
CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-156389000 | USD |
CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
15061000 | USD |
CY2018 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
18725000 | USD |
CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
225000000 | shares |
CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
225000000 | shares |
CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
106000 | USD |
CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
106000 | USD |
CY2016 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-131421000 | USD |
CY2017 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-123020000 | USD |
CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-120338000 | USD |
CY2016 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
0 | USD |
CY2017 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1899000 | USD |
CY2018 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2491000 | USD |
CY2018Q4 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
8.442 | |
CY2014Q4 | us-gaap |
Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
|
118.4553 | |
CY2017Q4 | us-gaap |
Debt Instrument Description
DebtInstrumentDescription
|
200000 | |
CY2017Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
150000000 | USD |
CY2018Q4 | us-gaap |
Debt Instrument Fair Value
DebtInstrumentFairValue
|
97500000 | USD |
CY2018Q4 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.09 | |
CY2014Q4 | us-gaap |
Debt Instrument Term
DebtInstrumentTerm
|
P7Y | |
CY2017Q4 | us-gaap |
Debt Instrument Term
DebtInstrumentTerm
|
P5Y | |
CY2018Q3 | us-gaap |
Debt Instrument Term
DebtInstrumentTerm
|
P2Y | |
CY2018Q4 | us-gaap |
Deferred Finance Costs Gross
DeferredFinanceCostsGross
|
3200000 | USD |
CY2017Q4 | us-gaap |
Deferred Finance Costs Gross
DeferredFinanceCostsGross
|
4100000 | USD |
CY2018Q4 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
4913000 | USD |
CY2016 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | USD |
CY2017 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-12661000 | USD |
CY2018 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | USD |
CY2017Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
10897000 | USD |
CY2018Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
10527000 | USD |
CY2017Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
40351000 | USD |
CY2018Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
3395000 | USD |
CY2017Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
24903000 | USD |
CY2018Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
23651000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
13523000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
5458000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
346642000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
68603000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
71047000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
183839000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
206789000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
455800000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
5656000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
6044000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
46574000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
47087000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3923000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
4641000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
341759000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
364702000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
369215000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
6014000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
6014000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
6014000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
|
6014000 | USD |
CY2017Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
1000 | USD |
CY2018Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
2000 | USD |
CY2016 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
700000 | USD |
CY2017 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
1000000 | USD |
CY2018 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
1000000 | USD |
CY2016 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2056000 | USD |
CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3399000 | USD |
CY2018 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3683000 | USD |
CY2016 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.27 | |
CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.31 | |
CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.33 | |
CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.28 | |
CY2017Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.25 | |
CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.17 | |
CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.40 | |
CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.33 | |
CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.26 | |
CY2018Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.16 | |
CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.14 | |
CY2018Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
22300000 | USD |
CY2018 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y2M | |
CY2017 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-703000 | USD |
CY2018 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
2101000 | USD |
CY2017 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
-3200000 | USD |
CY2018 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
-21013000 | USD |
CY2016Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
22815000 | USD |
CY2017Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
18912000 | USD |
CY2018Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
0 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
12654000 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
1766000 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
1766000 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
1766000 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
1766000 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
1766000 | USD |
CY2018Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
21484000 | USD |
CY2016 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-16000 | USD |
CY2017 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-3000 | USD |
CY2018 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
0 | USD |
CY2018Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | USD |
CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
43157000 | USD |
CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
66090000 | USD |
CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
63754000 | USD |
CY2017Q4 | us-gaap |
Goodwill
Goodwill
|
44543000 | USD |
CY2018Q4 | us-gaap |
Goodwill
Goodwill
|
44543000 | USD |
CY2016 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2017 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2018 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | USD |
CY2016 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | USD |
CY2017 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | USD |
CY2018 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | USD |
CY2016 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-131445000 | USD |
CY2017 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-135654000 | USD |
CY2018 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-120548000 | USD |
CY2016 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
13584000 | USD |
CY2017 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-11875000 | USD |
CY2018 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-18857000 | USD |
CY2016 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4080000 | USD |
CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-166000 | USD |
CY2018 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1099000 | USD |
CY2016 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-69262000 | USD |
CY2017 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-51133000 | USD |
CY2018 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-23996000 | USD |
CY2016 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
0 | USD |
CY2017 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1948000 | USD |
CY2018 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2732000 | USD |
CY2016 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
32000 | USD |
CY2017 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-33000 | USD |
CY2018 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-144000 | USD |
CY2016 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-6259000 | USD |
CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
557000 | USD |
CY2018 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1766000 | USD |
CY2016 | us-gaap |
Interest Expense
InterestExpense
|
6567000 | USD |
CY2017 | us-gaap |
Interest Expense
InterestExpense
|
6984000 | USD |
CY2017 | us-gaap |
Interest Paid Net
InterestPaidNet
|
5870000 | USD |
CY2018 | us-gaap |
Interest Expense
InterestExpense
|
20777000 | USD |
CY2016 | us-gaap |
Interest Paid Net
InterestPaidNet
|
6050000 | USD |
CY2018 | us-gaap |
Interest Paid Net
InterestPaidNet
|
16465000 | USD |
CY2017Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1183000 | USD |
CY2018Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
884000 | USD |
CY2017Q4 | us-gaap |
Inventory Gross
InventoryGross
|
1948000 | USD |
CY2018Q4 | us-gaap |
Inventory Gross
InventoryGross
|
4680000 | USD |
CY2017Q4 | us-gaap |
Inventory Net
InventoryNet
|
1948000 | USD |
CY2018Q4 | us-gaap |
Inventory Net
InventoryNet
|
4680000 | USD |
CY2017Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
616000 | USD |
CY2018Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
3564000 | USD |
CY2017Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
149000 | USD |
CY2018Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
232000 | USD |
CY2017Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
310788000 | USD |
CY2018Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
160052000 | USD |
CY2016 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
500000 | USD |
CY2017 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
600000 | USD |
CY2018 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
600000 | USD |
CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
368274000 | USD |
CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
310541000 | USD |
CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
436539000 | USD |
CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
284136000 | USD |
CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
105489000 | USD |
CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
36751000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
249915000 | USD |
CY2017Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
14094000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
1115000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
|
0 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
1285000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
|
0 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
150000000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
87500000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
11130000 | USD |
CY2017Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
231576000 | USD |
CY2018Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
243887000 | USD |
CY2018Q4 | us-gaap |
Mortgage Loans On Real Estate
MortgageLoansOnRealEstate
|
12100000 | USD |
CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
987000 | USD |
CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
149933000 | USD |
CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2244000 | USD |
CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
18252000 | USD |
CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
50522000 | USD |
CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
169576000 | USD |
CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-175628000 | USD |
CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-185394000 | USD |
CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-148607000 | USD |
CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-131445000 | USD |
CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31918000 | USD |
CY2017Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26609000 | USD |
CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-122993000 | USD |
CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-41822000 | USD |
CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-34549000 | USD |
CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27396000 | USD |
CY2018Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16781000 | USD |
CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-34657000 | USD |
CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29809000 | USD |
CY2017Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-29016000 | USD |
CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
285000 | USD |
CY2016 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
24000 | USD |
CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-130624000 | USD |
CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-37713000 | USD |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-120548000 | USD |
CY2017 | us-gaap |
New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
|
0 | USD |
CY2018 | us-gaap |
New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
|
14212000 | USD |
CY2018 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
206427000 | USD |
CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
222313000 | USD |
CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
166488000 | USD |
CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-127171000 | USD |
CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-39512000 | USD |
CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-33491000 | USD |
CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28605000 | USD |
CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-30272000 | USD |
CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-22927000 | USD |
CY2018Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12367000 | USD |
CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-103279000 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
2598000 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
657000 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
0 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
658000 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
646000 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
637000 | USD |
CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
0 | USD |
CY2018Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
941900000 | USD |
CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
4434000 | USD |
CY2018Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
2668000 | USD |
CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
429000 | USD |
CY2017 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-27000 | USD |
CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1954000 | USD |
CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3508000 | USD |
CY2014Q4 | us-gaap |
Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
|
3400000 | USD |
CY2016 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
621000 | USD |
CY2017 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
1679000 | USD |
CY2018 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
972000 | USD |
CY2016 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
425673000 | USD |
CY2017 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
267873000 | USD |
CY2018 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
119987000 | USD |
CY2018 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
210000 | USD |
CY2017Q4 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
51885000 | USD |
CY2018Q4 | us-gaap |
Other Intangible Assets Net
OtherIntangibleAssetsNet
|
50119000 | USD |
CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
292000 | USD |
CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
238000 | USD |
CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
2293000 | USD |
CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
231000 | USD |
CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
228000 | USD |
CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
95000 | USD |
CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | USD |
CY2014Q4 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
87500000 | USD |
CY2016 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3624000 | USD |
CY2017 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
7987000 | USD |
CY2018 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
732000 | USD |
CY2016 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
0 | USD |
CY2017 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
145905000 | USD |
CY2018 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
12529000 | USD |
CY2016 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
444156000 | USD |
CY2017 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
318623000 | USD |
CY2018 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
289658000 | USD |
CY2016 | us-gaap |
Profit Loss
ProfitLoss
|
-131445000 | USD |
CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-122993000 | USD |
CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-120548000 | USD |
CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
76310000 | USD |
CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
75871000 | USD |
CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
17687000 | USD |
CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15865000 | USD |
CY2017 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
152223000 | USD |
CY2018 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
36271000 | USD |
CY2018Q3 | us-gaap |
Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
|
P10Y | |
CY2018 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
100243000 | USD |
CY2016 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
0 | USD |
CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1365241000 | USD |
CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1471577000 | USD |
CY2017 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
7000 | USD |
CY2018 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
0 | USD |
CY2016 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
0 | USD |
CY2016 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
2016000 | USD |
CY2017 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
15890000 | USD |
CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
26583000 | USD |
CY2016 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
79101000 | USD |
CY2017 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
75621000 | USD |
CY2017 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
2280000 | USD |
CY2018 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
14533000 | USD |
CY2016 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
163973000 | USD |
CY2016 | us-gaap |
Revenues
Revenues
|
79256000 | USD |
CY2017Q1 | us-gaap |
Revenues
Revenues
|
17962000 | USD |
CY2017Q2 | us-gaap |
Revenues
Revenues
|
12087000 | USD |
CY2017Q3 | us-gaap |
Revenues
Revenues
|
27674000 | USD |
CY2017Q4 | us-gaap |
Revenues
Revenues
|
33966000 | USD |
CY2017 | us-gaap |
Revenues
Revenues
|
91689000 | USD |
CY2018Q1 | us-gaap |
Revenues
Revenues
|
25374000 | USD |
CY2018Q2 | us-gaap |
Revenues
Revenues
|
13798000 | USD |
CY2018Q3 | us-gaap |
Revenues
Revenues
|
6966000 | USD |
CY2018Q4 | us-gaap |
Revenues
Revenues
|
17071000 | USD |
CY2018 | us-gaap |
Revenues
Revenues
|
63209000 | USD |
CY2016 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
155000 | USD |
CY2017 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
178000 | USD |
CY2018 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
355000 | USD |
CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7452000 | USD |
CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9472000 | USD |
CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11696000 | USD |
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
7438134 | shares |
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
4583555 | shares |
CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1700000 | USD |
CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2000000 | USD |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | USD |
CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.43 | |
CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
8.59 | |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.63 | |
CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
300000 | USD |
CY2018Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
300000 | USD |
CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y2M | |
CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y7M | |
CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
249127000 | USD |
CY2018Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
79666000 | USD |
CY2016 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
6125000 | USD |
CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
167507000 | USD |
CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68265000 | USD |
CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-26405000 | USD |
CY2017Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
122000 | shares |
CY2018Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
236000 | shares |
CY2017 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
5486000 | USD |
CY2018 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
732000 | USD |
CY2017Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
1904000 | USD |
CY2018Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
2876000 | USD |
CY2017 | us-gaap |
Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
|
0 | USD |
CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
285972000 | USD |
CY2016 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
621000 | USD |
CY2017 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
1679000 | USD |
CY2018 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
972000 | USD |
CY2018Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
1400000 | USD |
CY2016 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
24000 | USD |
CY2017 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-27000 | USD |
CY2018 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
210000 | USD |
CY2017Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | USD |
CY2018Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | USD |
CY2018 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-22900000 | USD |
CY2016 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
103863000 | shares |
CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
104461000 | shares |
CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105300000 | shares |
CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105582000 | shares |
CY2017Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105588000 | shares |
CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105237000 | shares |
CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105668000 | shares |
CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105848000 | shares |
CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105881000 | shares |
CY2018Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105920000 | shares |
CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
105830000 | shares |
CY2018 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div> |